161 related articles for article (PubMed ID: 2690972)
41. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.
Paterson AH; Hanson J; Pritchard KI; Sansregret E; Dahrouge S; McDermot RS; Fine S; White DF; Trudeau M; Stewart DJ
Semin Oncol; 1990 Dec; 17(6 Suppl 9):52-62. PubMed ID: 2259927
[TBL] [Abstract][Full Text] [Related]
42. Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer.
Samonis G; Margioris AN; Bafaloukos D; Razis DV
Oncology; 1994; 51(5):411-5. PubMed ID: 8052481
[TBL] [Abstract][Full Text] [Related]
43. [Which hormone therapy should be used in advanced breast carcinoma in males?].
Lönning PE; Wiedemann G; Kvinnsland S; Lundgren S
Dtsch Med Wochenschr; 1988 Sep; 113(35):1358-61. PubMed ID: 2970379
[TBL] [Abstract][Full Text] [Related]
44. Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments.
Zambetti M; Brambilla C; Tancini G; Bonadonna G
Tumori; 1987 Aug; 73(4):369-73. PubMed ID: 3660475
[TBL] [Abstract][Full Text] [Related]
45. Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity.
Rowell NP; Gilmore OJ; Plowman PN
Hum Toxicol; 1987 May; 6(3):227-32. PubMed ID: 3596607
[TBL] [Abstract][Full Text] [Related]
46. Aminoglutethimide in treatment of metastatic breast carcinoma.
Smith IE; Fitzharris BM; McKinna JA; Fahmy DR; Nash AG; Neville AM; Gazet JC; Ford HT; Powles TJ
Lancet; 1978 Sep; 2(8091):646-9. PubMed ID: 80576
[TBL] [Abstract][Full Text] [Related]
47. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
[TBL] [Abstract][Full Text] [Related]
48. Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
Horton J; Knuiman M; Keller AM; Vogel H; Gale KE; Hahn RG; Rosenbluth RJ; Tormey DC
Cancer; 1987 Nov; 60(9):2137-40. PubMed ID: 3440224
[TBL] [Abstract][Full Text] [Related]
49. [The use of aminoglutethimide (orimeten) in disseminated breast cancer].
Nadezhdina TM; Vyshinskaia GV; Lichinitser MR; Bassalyk LS; Garin AM
Vopr Onkol; 1987; 33(5):79-82. PubMed ID: 3590672
[TBL] [Abstract][Full Text] [Related]
50. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
[TBL] [Abstract][Full Text] [Related]
51. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen.
Ross MB; Buzdar AU; Blumenschein GR
Cancer; 1982 Feb; 49(3):413-7. PubMed ID: 6174195
[TBL] [Abstract][Full Text] [Related]
52. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.
Canney PA; Priestman TJ; Griffiths T; Latief TN; Mould JJ; Spooner D
J Natl Cancer Inst; 1988 Sep; 80(14):1147-51. PubMed ID: 2970555
[TBL] [Abstract][Full Text] [Related]
53. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment.
Blackledge GR; Latief T; Mould JJ; Spooner D; Morrison M
Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1091-4. PubMed ID: 2946584
[TBL] [Abstract][Full Text] [Related]
54. The role of progestins in the treatment of breast cancer.
Blumenschein GR
Semin Oncol; 1983 Dec; 10(4 Suppl 4):7-10. PubMed ID: 6230722
[TBL] [Abstract][Full Text] [Related]
55. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
56. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer.
Ingle JN; Ahmann DL; Green SJ; Edmonson JH; Creagan ET; Hahn RG; Rubin J
Am J Clin Oncol; 1982 Apr; 5(2):155-60. PubMed ID: 7046412
[TBL] [Abstract][Full Text] [Related]
57. Aminoglutethimide as second line therapy in advanced breast cancer.
Elomaa I; Blomqvist C; Rissanen P
Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
[TBL] [Abstract][Full Text] [Related]
58. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.
Bonomi P; Johnson P; Anderson K; Wolter J; Bunting N; Strauss A; Roseman D; Shorey W; Economou S
Semin Oncol; 1985 Mar; 12(1 Suppl 1):48-54. PubMed ID: 3975653
[TBL] [Abstract][Full Text] [Related]
59. Could aminoglutethimide replace adrenalectomy?
Harris AL
Breast Cancer Res Treat; 1985; 6(3):201-11. PubMed ID: 3912013
[TBL] [Abstract][Full Text] [Related]
60. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.
Lundgren S; Lønning PE; Aakvaag A; Kvinnsland S
Cancer Chemother Pharmacol; 1990; 27(2):101-5. PubMed ID: 2249324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
